Procept BioRobotics shares soared 30% on Wednesday after the company said its robotic system designed to treat benign prostatic hyperplasia received clearance from the Food and Drug Administration (FDA).

Bicara Therapeutics and Zenas Biopharma have provided fresh impetus to the IPO market with filings that illustrate what newly public biotechs may look like in the back half of 2024.

Mechanical ventilation, the use of a machine to help a person breathe, was not something many people thought about all that often—until the COVID pandemic struck. Stories of patients being put on ventilators, along with associated shortages of these machines, were blasted across the news, thrusting this decades-old treatment into the spotlight.

Eli Lilly has expanded its partnership with Oblique Therapeutics, adding a second strand to an alliance focused on using the AbiProt platform to discover antibodies against high-value targets.

With just weeks to go before the FDA decides whether to approve the first treatment for a rare genetic condition, Rafael Holdings is merging with Cyclo Therapeutics to try to push their own candidate over the line.

Novartis’ $3.2 billion deal for Chinook Therapeutics gave the Swiss Big Pharma such a taste for kidney disease-focused biotechs that it has partnered with VC firm Versant Ventures to create another company in a similar mold.

Roche says it’s actively working with its partners to enhance mpox laboratory capacity worldwide to develop diagnostic tests to combat the outbreak.

BioMarin Pharmaceutical is shaking up its leadership team, raiding Amgen for an R&D chief to replace a departing company veteran and pulling off the coup of signing a high-profile former Roche dealmaker.

The FDA has thrown a wrench in Regeneron’s plans to challenge Johnson & Johnson and Pfizer in a blood cancer market, hitting the Big Biotech with a complete response letter over issues at a third-party manufacturer.

Windtree Therapeutics’ roots may have received some urgently needed financial watering last month thanks to a private placement of its stock, but the biotech still doesn’t have enough money to keep its pipeline of cardiovascular meds in health for more than a year.